Dyadic International Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Jupiter, fla., march 28, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent company progress.

Jupiter, fla., march 28, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that michael tarnok is stepping down as chairman of dyadic's board of directors (the “board”) and that current member of the board patrick lucy has been appointed to succeed him, in each case, effective immediately. mr. tarnok will continue to serve as a director through the end of his current term, which will end at the company's annual meeting in june 2025, at which time he expects to retire...

Jupiter, fla., march 27, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry events during the month of april 2024.

Jupiter, fla., march 26, 2024 (globe newswire) -- dyadic international, inc. (“dyadic” or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript "filamentous fungus-produced human monoclonal antibody provides protection against sars-cov-2 in hamster and nonhuman primate models" in nature communications (“springer-nature"), an international journal publishing peer-reviewed research in all fields of science and technology.

Jupiter, fla., march 21, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that joseph hazelton, chief business officer and doug pace, executive vice president of business development will be attending the future food-tech “innovation & investment from farm to fork” event march 21 – 22, 2024 at the san francisco marriott marquis in california.

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.

JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the month of February 2024.

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution”  Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic...

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic...

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.